Skip NavigationSkip to Content
Return Return to Search Results

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

  1. Author:
    Crea, F.
    Hurt, E. M.
    Mathews, L. A.
    Cabarcas, S. M.
    Sun, L.
    Marquez, V. E.
    Danesi, R.
    Farrar, W. L.

  2. Author Address

    [Crea, F; Mathews, LA; Cabarcas, SM; Sun, L; Farrar, WL] NCI, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA [Hurt, EM] Medimmune Inc, Gaithersburg, MD 20878 USA [Marquez, VE] NCI, Biol Chem Lab, Ctr Canc Res, Frederick, MD 21701 USA [Danesi, R] Pisa Med Sch, Div Pharmacol, Dept Internal Med, Pisa, Italy;Farrar, WL (reprint author), NCI, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA;farrarw@mail.nih.gov
    1. Year: 2011
    2. Date: Apr
  2. Journal: Molecular Cancer
    1. 10
    2. Pages: 10
  4. Type of Article: Article
  5. Article Number: 40
  6. ISSN: 1476-4598
  1. Abstract:

    Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with broad anticancer activity. Method: we investigated the effects of DZNeP on cell proliferation, tumorigenicity and invasive potential of PC cell lines (LNCaP and DU145). Results: Exploring GEO and Oncomine databases, we found that specific PRC2 genes (EED, EZH2, SUZ12) predict poor prognosis in PC. Non-toxic DZNeP concentrations completely eradicated LNCaP and DU145 prostatosphere formation, and significantly reduced the expression of CSC markers. At comparable doses, other epigenetic drugs were not able to eradicate CSCs. DZNeP was also able to reduce PC cell invasion. Cells pre-treated with DZNeP were significantly less tumorigenic (LNCaP) and formed smaller tumors (DU145) in immunocompromised mice. Conclusion: DZNeP is effective both in vitro and in vivo against PC cells. DZNeP antitumor activity is in part mediated by inhibition of CSC tumorigenic potential.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1186/1476-4598-10-40
  3. View record in Web of Science®
  4. WOS: 000290865200001

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel